Anti-programmed Cell Death Receptor 1
2 clinical trials · Condition
◉ Watch Anti-programmed Cell Death Receptor 1
| Record | Firm | Date |
|---|---|---|
| PD-1 Antibody Plus Chemoradiotherapy for IB2-IIIB Cervical Cancer (NCT05311566) | Lei Li | 2022-03-27 |
| Tislelizumab and Radiotherapy for Recurrent Cervical Cancer (NCT05310383) | Lei Li | 2022-03-27 |
Track Anti-programmed Cell Death Receptor 1 automatically
Every clearance here is in the API, with alerts when new ones post.